Compounds > 2-({2-[(3-hydroxyphenyl)amino]pyrimidin-4-yl}amino)benzamide

2-({2-[(3-hydroxyphenyl)amino]pyrimidin-4-yl}amino)benzamide and Diabetes-Mellitus--Type-2

2-({2-[(3-hydroxyphenyl)amino]pyrimidin-4-yl}amino)benzamide has been researched along with Diabetes-Mellitus--Type-2* in 1 studies

Other Studies

1 other study(ies) available for 2-({2-[(3-hydroxyphenyl)amino]pyrimidin-4-yl}amino)benzamide and Diabetes-Mellitus--Type-2

ArticleYear
Novel compounds reducing IRS-1 serine phosphorylation for treatment of diabetes.
    Bioorganic & medicinal chemistry letters, 2016, Jan-15, Volume: 26, Issue:2

    Activation of various interacting stress kinases, particularly the c-Jun N-terminal kinases (JNK), and a concomitant phosphorylation of insulin receptor substrate 1 (IRS-1) at serine 307 play a central role both in insulin resistance and in β-cell dysfunction. IRS-1 phosphorylation is stimulated by elevated free fatty acid levels through different pathways in obesity. A series of novel pyrido[2,3-d]pyrimidin-7-one derivatives were synthesized as potential antidiabetic agents, preventing IRS-1 phosphorylation at serine 307 in a cellular model of lipotoxicity and type 2 diabetes.

    Topics: Diabetes Mellitus, Type 2; HEK293 Cells; Humans; Hypoglycemic Agents; Insulin Receptor Substrate Proteins; JNK Mitogen-Activated Protein Kinases; Phosphorylation; Pyrimidines; Serine

2016